Hoo Cheung Industries Ltd v. Sharda Cropchem Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: BASF Corporation (Delaware) and Basf Se (Germany)
  • Defendant: Sharda Cropchem Ltd. (India) and Sharda USA LLC (Delaware)
  • Plaintiff's Counsel: Weil, Gotshal & Manges LLP
• Case Identification: 1:22-cv-00120, D. Del., 01/28/2022
• Venue Allegations: Venue is alleged to be proper in Delaware because Defendant Sharda USA LLC is a Delaware corporation, and Defendant Sharda Cropchem Ltd. is a foreign entity for which venue is proper in any district.
• Core Dispute: Plaintiff alleges that Defendant's pyraclostrobin-based fungicide products infringe a patent directed to a specific crystalline form of the pyraclostrobin chemical compound.
• Technical Context: The technology relates to chemical polymorphism, where a specific crystalline structure of an active ingredient in an agrochemical product can provide superior stability and formulation properties.
• Key Procedural History: The complaint notes that BASF received EPA registrations for its own pyraclostrobin products beginning in 2002 and that one of its commercial products, Headline® SC, is marked with the patent-in-suit. The complaint also alleges that Defendant Sharda received EPA approval for its accused end-use products on November 10, 2021.

Case Timeline

Date	Event
2002-09-30	Plaintiff BASF receives EPA registration for its pyraclostrobin technical product Compl. ¶28
2005-06-20	'392 Patent Priority Date
2007-10-03	Plaintiff BASF receives EPA registration for its "BAS 500 F Crystalline" product Compl. ¶29
2010-10-19	'392 Patent Issue Date
2021-02-05	Defendant Sharda USA LLC receives shipment of accused PREACH™ product in the U.S. Compl. ¶17
2021-10-05	Plaintiff BASF receives EPA registration for its "Pyraclostrobin Dry Crystalline 1" product Compl. ¶30
2021-11-10	EPA approves Defendant Sharda's end-use registrations for certain accused products Compl. ¶38
2022-01-28	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,816,392 - "Crystalline Modifications to Pyraclostrobin"

• Patent Identification: United States Patent No. 7,816,392 (the "'392 Patent"), titled "Crystalline Modifications to Pyraclostrobin", was issued on October 19, 2010 Compl. ¶33

The Invention Explained

• Problem Addressed: The patent's background section explains that commercially available pyraclostrobin is an "amorphous substance of low melting point" Patent, col. 1:12-13 This "tackiness" makes it unsuitable for creating stable aqueous suspension concentrates, a common type of agrochemical formulation, as it can cause grinding equipment to "get stuck" Patent, col. 1:15-20 Alternative solvent-based formulations are described as problematic for environmental and work hygiene reasons Patent, col. 1:25-34
• The Patented Solution: The invention provides pyraclostrobin in a specific, stable crystalline form, designated "modification IV" Patent, abstract Patent, col. 1:45-51 This crystalline form is not tacky and enables the preparation of suspension concentrates with "improved stability" Patent, col. 1:48-51 The patent identifies this specific crystalline structure by the characteristic peaks it produces in an X-ray powder diffractogram Patent, col. 1:52-67
• Technical Importance: The development of a stable crystalline polymorph allows for the creation of more stable, solvent-free, and economically viable formulations of a commercially significant fungicidal active ingredient Compl. ¶35

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶43
• The essential elements of claim 1 are:
  • A crystalline modification IV of pyraclostrobin
  • which, in an X-ray powder diffractogram at 25° C.,
  • shows at least three of the following reflexes:
    • d=6.02±0.01 Å
    • d=4.78±0.01 Å
    • d=4.01±0.01 Å
    • d=3.55±0.01 Å
    • d=3.01±0.01 Å Compl. ¶44

III. The Accused Instrumentality

• Product Identification: The Accused Products include, but are not limited to, "Sharda Boscalid 25.2% + Pyraclostrobin 12.8% WG," "Sharda Boscalid 25.2% + Pyraclostrobin 12.8% WG II," "Sharda Pyraclostrobin 20% WG," "Sharda Pyraclostrobin 25% EC" (marketed as PREACH™), "Sharda Pyraclostrobin 20% SC," and "Sharda Pyraclostrobin Technical" Compl. ¶3
• Functionality and Market Context: The Accused Products are fungicides containing the active ingredient pyraclostrobin for controlling plant diseases Compl. ¶¶3, 10 The complaint alleges that Defendant Sharda is a global company focused on generic crop protection products and that it imports pyraclostrobin as a "technical (active ingredient) form" which is then formulated and packaged for the U.S. market Compl. ¶10 Compl. ¶17 Compl. ¶40

IV. Analysis of Infringement Allegations

The complaint's infringement allegations are made "upon information and belief" and are based on an inferential theory rather than direct analytical testing of the Accused Products presented in the complaint Compl. ¶¶43, 47, 49

The complaint includes a screenshot from a Safety Data Sheet for the accused product PREACH™, identifying it as containing "Pyraclostrobin 250 g/l EC" Compl. ¶45

'392 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A crystalline modification IV of pyraclostrobin	The complaint alleges the Accused Products contain crystalline modification IV because they contain pyraclostrobin as the active ingredient, and alleges that "the only known suppliers of active ingredient pyraclostrobin in the world produce and supply only crystalline modification IV." The complaint further alleges this form is more stable and suitable for the accused formulations.	¶¶47, 49	col. 1:52-53
which, in an X-ray powder diffractogram at 25° C., shows at least three of the following reflexes: d=6.02±0.01 Å; d=4.78±0.01 Å; d=4.01±0.01 Å; d=3.55±0.01 Å; d=3.01±0.01 Å.	The complaint alleges, upon information and belief, that the pyraclostrobin in the Accused Products will exhibit at least three of the five claimed reflexes because it is allegedly sourced from suppliers who only produce modification IV.	¶¶48, 50	col. 1:54-67

• Identified Points of Contention:
  • Evidentiary Question: The complaint's infringement theory rests on the premise that the only available pyraclostrobin on the global market is the patented modification IV Compl. ¶47 Compl. ¶49 A central point of contention will be whether Plaintiff can substantiate this claim and provide direct analytical evidence (e.g., X-ray powder diffraction data) from the Accused Products that confirms the presence of the claimed crystalline structure. The complaint does not present such data.
  • Technical Question: Assuming Plaintiff produces diffraction data, a dispute may arise over whether the observed reflexes in the accused material reliably match "at least three" of the five d-spacing values listed in the claim, within the specified tolerance of ±0.01 Å.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of potential claim construction disputes. However, based on the nature of the patent and allegations, the following term may be a focus.

• The Term: "shows at least three of the following reflexes"
• Context and Importance: This phrase defines the objective, measurable test for infringement. The manner in which an X-ray powder diffractogram is interpreted-specifically, how peaks are identified and counted to meet the "at least three" requirement-will be critical to the infringement analysis.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The plain language of the claim requires the presence of "at least three" of the five listed reflexes, suggesting that any combination of three would satisfy the limitation Patent, col. 25:61-62
  • Evidence for a Narrower Interpretation: A defendant might argue that the claim should be read in light of the patent's disclosure, which describes modification IV as showing "in particular at least 4 and preferably all of the following reflexes" Patent, col. 1:54-57 Further, a defendant could point to the full diffractogram in Figure 1, which shows a unique pattern of peaks with specific relative intensities, and argue that simply finding any three isolated reflexes is insufficient to prove the presence of the claimed "crystalline modification IV."

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that Defendants provide product labels (e.g., for PREACH™) that instruct and encourage end-users to apply the Accused Products to crops, thereby performing an infringing use Compl. ¶¶51-53
• Willful Infringement: The complaint alleges willful infringement based on alleged pre-suit knowledge of the '392 Patent Compl. ¶58 The basis for this allegation is that Defendants have marketed their PREACH™ product as using the "same active ingredient as Headline," and Plaintiff's Headline® SC product is marked with the '392 patent Compl. ¶54 The complaint also points to Defendants' EPA filings as an indication of awareness that the Accused Products are "identical or substantially similar" to BASF's patented products Compl. ¶54

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of evidentiary proof: The complaint's infringement case is built on the inferential premise that Sharda must be using the patented crystalline form because it is the only one available from global suppliers. The case will likely turn on whether BASF can, through discovery and expert analysis, produce direct and dispositive X-ray diffraction data from Sharda's products that proves they contain pyraclostrobin meeting the "at least three reflexes" limitation of claim 1.
• A second key question will relate to willfulness and pre-suit knowledge: Can BASF establish that Sharda's own marketing statements comparing its product to BASF's "Headline" brand, which is marked with the patent, constitute sufficient notice and knowledge to support a finding of willful infringement and potential eligibility for enhanced damages?